How VV913 behaves after different meals in healthy adults
Official title: Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers
Run by Vigonvita Life Sciences · NCT07565792 · Data updated 2026-11-12
This study tests how a single dose of VV913 is absorbed in healthy adult men when taken with a high-fat meal versus a standard meal.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 45 Years |
| Sex | Men only |
| Enrollment | 12 (estimated) |
| Sponsor | Vigonvita Life Sciences Industry-sponsored |
| Locations | 1 site (Hefei, Anhui) |
| Status | Recruiting |
| Started | May 11, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT07565792 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy male adults aged 18 to 45 with BMI 19–26 kg/m2 who can use contraception during the study and for 3 months after.
✕Probably not a fit
Individuals with known hypersensitivity to VV913 components or those with certain medical or allergic conditions may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, randomized, open-label, 3x3 crossover Phase 1 study conducted in healthy Chinese adults to compare the pharmacokinetics of one oral dose of VV913 after high-fat and standard meals. Participants receive VV913 under different meal conditions to see how food type affects drug absorption and exposure. The trial uses a crossover design so each participant experiences all meal conditions, reducing variability. Key safety assessments include vital signs, labs, and adverse events. The study is sponsored by Vigonvita Life Sciences and located at The First Affiliated Hospital of Anhui Medical University in Hefei.
Why it matters
Potential benefit: If successful, results could help optimize how VV913 is dosed with meals to improve consistent drug exposure.
How similar studies have gone: Similar crossover pharmacokinetic studies are common in early development to understand food effects on drug absorption.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18 to 45 years old, males ; 2. Males weight no less than 50 kg, with body mass index of 19 to 26 kg/m\^2; 3. Vital signs examination, physical examination, laboratory examination ,Chest X-ray are normal or considered abnormal without clinical significance by the investigator; 4. Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration; 5. Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form. Exclusion Criteria: 1. Participants with hypersensitivity to preparation or any of the excipients; 2. Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy; 3. Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; Participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction); 4. Participants with a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial; 5. Participants with a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a history of blood product use within 3 months before screening; 6. Participating in any clinical trial and taking clinical trial drugs within 90 days before screening; 7. Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before screening; 8. Participants who have received vaccination within 14 days before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study; 9. Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine); 10. Participants who drink more than 14 standard units or at least twice a day per week within one year before screening (one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content); 11. Participants who smoke more than 5 cigarettes a day within one year before screening; 12. Participants who can't quit smoking or drinking during the trial period; 13. Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV); 14. Having special requirements for food, unable to observe a unified diet or having dysphagia; 15. Participants who cannot avoid consuming drinks containing xanthine (such as coffee and tea) or foods (such as chocolate and animal liver), or fruits or juices (such as grapefruit, pomelo, mango, and dragon fruit) that may affect drug metabolism,from 48 hours before administration until the end of the study; 16. Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting; 17. Participants with difficulty in swallowing capsules; 18. Participants whose female partners plan to conceive within 3 months; 19. The investigator believes that there are other unsuitable factors to participate this trial.
Where it's running
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China Recruiting
Study contacts
- Principal investigator: Huan Zhou — The First Affiliated Hospital of Anhui Medical University
- Study coordinator: Huaqing Duan
- Email: huaqing.duan@vigonvita.cn
- Phone: 18061926005
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Safety and Pharmacokinetics of VV261 Tablets in Healthy Adults
This study tests how VV261 tablets behave and how safe they are in healthy adults, using a random, placebo-controlled design with escalating doses.
-
Safety and dosing of VV913 capsules in healthy adults
This study tests different doses of VV913 to see if it is safe and how it behaves in the body for healthy adult men in China.
-
Safety, tolerability, and dosing of VV913 capsules in healthy Chinese men
This test gives single, increasing doses of VV913 or placebo to healthy Chinese men aged 18–45 to see if the drug is safe and how the body processes it.
-
How a standard meal affects VV119 capsules in healthy adults
Researchers will test whether eating a standard meal changes how VV119 capsules are absorbed in healthy adult volunteers.
-
Evaluating LV232 Capsules for Treating Major Depressive Disorder
This study is testing different doses of LV232 capsules to see if they can help people with major depressive disorder feel better compared to a placebo and an active medication.
-
Evaluating the safety and effects of VV119 in schizophrenia patients
This study is testing a new drug called VV119 to see if it is safe and effective for adults with schizophrenia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.